Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FWMPN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
YL-202
|
|||||
| Synonyms |
YL 202; YL-202; YL202
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.Suzhou Medilink Therapeutics Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 4 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
An anti-HER3 IgG1 monoclonal antibody
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Tumor microenviroment activable tripeptide linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
B81
|
|||||
